The physiologically-based whole-body model of the glucose-insulin-glucagon regulatory system

Implementation of inhalation model in MoBi

Physiologically Based Pharmacokinetic Models for Pregnant Women

Whole-body PBPK model of midazolam as CYP3A4 DDI victim drug

Modeling of published clinical Clarithromycin-Midazolam-DDI studies for model evaluation

Whole-body PBPK model of digoxin as P-gp DDI victim drug

Modeling of published clinical Clarithromycin-Digoxin-DDI studies for model evaluation

Whole-body PBPK model of rifampicin as CYP3A4 and P-gp DDI perpetrator drug

Verapamil PBPK model

Whole-body PBPK model of efavirenz as CYP3A4 perpetrator drug

Modeling of published clinical Itraconazole-Digoxin-DDI studies for model evaluation

Modeling of published clinical Cimetidine-Carbamazepine DDI studies for model evaluation

Whole-body PBPK model of alfentanil as CYP3A4 DDI victim drug

Whole-body PBPK model of triazolam

Whole-body PBPK model of clarithromycin as CYP3A4 and P-gp DDI perpetrator drug

Whole-body PBPK model of fluvoxamine as CYP1A2 and CYP3A4 DDI perpetrator drug

Whole-body PBPK model of cimetidine (OCT2/MATE and CYP3A4 DDI perpetrator drug)